Johnson and Johnson: Carvykti is the First and Only Cell Therapy to Significantly Extend Overall Survival Versus Standard Therapies for Patients With Multiple Myeloma as Early as Second Line
September 28, 2024
September 28, 2024
NEW BRUNSWICK, New Jersey, Sept. 28 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
45 percent reduction in risk of death achieved with CARVYKTI after three-year follow-up in landmark CARTITUDE-4 study
Data featured in a late-breaking oral presentation at the 2024 International Myeloma Society Annual Meeting
* * *
RIO DE JANEIRO (September 27, 2024) - Johnson & Johnson (NYSE:JNJ) announced today long-te . . .
* * *
45 percent reduction in risk of death achieved with CARVYKTI after three-year follow-up in landmark CARTITUDE-4 study
Data featured in a late-breaking oral presentation at the 2024 International Myeloma Society Annual Meeting
* * *
RIO DE JANEIRO (September 27, 2024) - Johnson & Johnson (NYSE:JNJ) announced today long-te . . .